Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Capital Expenditures (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Capital Expenditures for 7 consecutive years, with -$6.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 257.66% year-over-year to -$6.2 million, compared with a TTM value of $1.6 million through Dec 2025, down 76.88%, and an annual FY2025 reading of $1.6 million, down 76.88% over the prior year.
  • Capital Expenditures was -$6.2 million for Q4 2025 at Avidity Biosciences, down from $5.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $5.4 million in Q3 2025 and bottomed at -$6.2 million in Q4 2025.
  • Average Capital Expenditures over 5 years is $763150.0, with a median of $882500.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures surged 2760.0% in 2021, then tumbled 495.88% in 2023.
  • Year by year, Capital Expenditures stood at $1.7 million in 2021, then crashed by 50.21% to $850000.0 in 2022, then crashed by 495.88% to -$3.4 million in 2023, then surged by 216.37% to $3.9 million in 2024, then plummeted by 257.66% to -$6.2 million in 2025.
  • Business Quant data shows Capital Expenditures for RNA at -$6.2 million in Q4 2025, $5.4 million in Q3 2025, and -$1.4 million in Q2 2025.